CN107307214A - 一种治疗猪腹泻的饲料添加剂 - Google Patents
一种治疗猪腹泻的饲料添加剂 Download PDFInfo
- Publication number
- CN107307214A CN107307214A CN201710748510.0A CN201710748510A CN107307214A CN 107307214 A CN107307214 A CN 107307214A CN 201710748510 A CN201710748510 A CN 201710748510A CN 107307214 A CN107307214 A CN 107307214A
- Authority
- CN
- China
- Prior art keywords
- feed addictive
- nevadensin
- berberine
- pigs
- feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 22
- 241000282887 Suidae Species 0.000 title claims abstract description 17
- KRFBMPVGAYGGJE-UHFFFAOYSA-N nevadensin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C(OC)=C2O1 KRFBMPVGAYGGJE-UHFFFAOYSA-N 0.000 claims abstract description 41
- FRZBKSSGEGEIAN-UHFFFAOYSA-N nevadensin Natural products COc1cccc(c1)-c1cc(=O)c2c(O)c(OC)c(O)c(OC)c2o1 FRZBKSSGEGEIAN-UHFFFAOYSA-N 0.000 claims abstract description 41
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940093265 berberine Drugs 0.000 claims abstract description 33
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 10
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 239000000654 additive Substances 0.000 abstract description 4
- 230000000996 additive effect Effects 0.000 abstract description 4
- 239000003674 animal food additive Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 235000021590 normal diet Nutrition 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241000233045 Lysionotus pauciflorus Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 244000247747 Coptis groenlandica Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000001355 anti-mycobacterial effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 150000003836 berberines Chemical group 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229940007046 shigella dysenteriae Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010061166 Gastroenteritis bacterial Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- -1 Oxygen radical Chemical class 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940090588 amoxil Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及一种防治猪腹泻的饲料添加剂,其中活性成分黄连素与石吊兰素的重量比为(1:10)~(10:1)。与普通饲料添加剂相比,本发明的猪饲料添加剂制备方法简单,配伍合理,疗效显著,能够显著降低猪腹泻率。由于添加剂中无西药成分,因此饲料添加剂无毒副作用,无耐药性。
Description
技术领域
本发明涉及饲料领域,具体涉及一种猪饲料添加剂。
背景技术
猪腹泻病是因猪感染病毒产生的,各种年龄的猪都能感染发病。哺乳猪、架子猪或肥育猪的发病率很高,尤以哺乳猪受害最为严重,母猪发病率变动很大。病猪是主要传染源,病毒存在于肠绒毛上皮细胞和肠系膜淋巴结,随粪便排出后,污染环境、饲料、饮水、交通工具及用具等而传染。如果一个猪场陆续有不少窝仔猪出生或断奶,病毒会不断感染失去母源抗体的断奶仔猪,使本病呈地方流行性,在这种繁殖场内,猪流行性腹泻可造成5-8周龄仔猪的断奶期顽固性腹泻。
抗生素是治疗猪腹泻病的主要饲料添加剂,其在防病治病的同时,还具有促进动物生长、提高饲料转化率的功效。除此之外,还有提高动物产品的品质,减少动物的粪臭,从而改善饲养环境等功效。但是,随着抗生素作为饲料添加剂使用的日益增加,也出现了反对将抗生素作为饲料添加剂使用的意见。研究人员认为对食用动物长时间低剂量地使用抗生素,无论用作饲料添加剂还是预防用药,都比短时间大剂量治疗用药更会引起生态环境对耐药菌的筛选,并且细菌中耐药基因可以在人群中细菌、动物群中细菌和生态系统中细菌间互相传递,由此可导致致病菌产生耐药性,从而引起人类和动物感染疾病治疗的失败。
相关研究表明,中草药所含活性物质能增强机体免疫力,提高动物抗应激、抗疾病能力,改善动物生产性能,且中药与食物同源,具有毒副作用小,不易产生耐药性,不会在肉、蛋、奶等畜产品种产生有害残留等优点,是抗菌药物及化学促生长剂的理想替代品。
黄连素是一种重要的生物碱,是我国应用很久的中药,可从黄连、黄柏、三颗针等植物中提取,它具有显著的抑菌作用,常用的盐酸黄连素又叫盐酸小檗碱。黄连素能对抗病原微生物,对多种细菌如痢疾杆菌、结核杆菌、肺炎球菌、伤寒杆菌及白喉杆菌等都有抑制作用,其中对痢疾杆菌作用最强,常用来治疗细菌性胃肠炎、痢疾等消化道疾病。临床主要用于治疗细菌性痢疾和肠胃炎,它副作用较小。
黄连素对于消化系统的作用还体现在治疗消化性溃疡、消化系统肿瘤、结肠炎等疾病方面。
黄连素促进了胃溃疡大鼠溃疡创面的愈合。据文献报道,黄连素与奥美拉唑胶囊、阿莫西林胶囊、克拉霉素片联合应用治疗2型糖尿病合并幽门螺旋杆菌感染型消化性溃疡患者,结果发现,黄连素显著提高消化性溃疡的临床疗效。但其作用机制不清,推测可能与黄连素的抗炎、抗氧化、减轻自由基损伤有关。
黄连素对消化系统肿瘤如:食管癌、胃癌、结肠癌等均有治疗作用。其作用机制包括:(1)抑制线粒体能量产生影响细胞的增殖。体外实验发现黄连素能抑制鼠结肠癌细胞的增殖,同时伴随细胞内及线粒体内三磷酸腺苷(ATP)水平的降低。(2)通过多种途径诱导癌变细胞的凋亡。黄连素通过上调胃癌细胞中凋亡基因Bax的表达和抑制Bcl-2的表达,诱导细胞凋亡。黄连素也可通过促进炎症因子的增加诱导肿瘤细胞的凋亡,还可通过DNA链的断裂诱发凋亡,发挥其治癌作用。此外,黄连素也可通过促进COX-2的表达诱导肿瘤细胞的凋亡。(3)影响肿瘤细胞的转移。肿瘤内新生血管可促进肿瘤细胞的增殖和转移。血管内皮生长因子和低氧诱导因子在血管生成中起到重要作用。黄连素能降低肿瘤细胞内血管内皮生长因子和低氧诱导因子的表达,抑制了新生血管的形成从而降低了癌细胞的侵袭能力。
黄连素能够减轻葡萄糖硫酸钠(DSS)诱导的小鼠结肠粘膜的损伤,作用机制可能是通过其抗氧化作用抑制了小鼠结肠粘膜炎性细胞的浸润,减轻了DSS诱导的小鼠结肠粘膜的炎症反应。
石吊兰素(nevadensin),又名岩豆素,是从中草药提取分离得到的一种黄酮化合物,其化学名5,7-二羟基-4’,6,8-三甲氧基黄酮,分子式为C18H16O7,相对分子量为344,黄色针晶(丙酮),熔点为195-196℃,无臭,无味,溶于5%Na2CO3,KOH或NaOH溶液,略溶于氯仿,微溶于甲醇、乙醇及乙酸乙酯,极微溶于乙醚,与镁粉-盐酸显樱红色。石吊兰素在植物体中以游离形式存在或与糖结合成甙的形式存在。
石吊兰素在化学结构上虽有酚羟基而具弱酸性,但对石吊兰素的提取多利用其物理化学特性。如将石吊兰用水煮沸3次后的药渣,用95%乙醇回流提取3次,每次2h,滤液减压浓缩,有黄色粉末析出,吸滤,用丙酮反复重结晶,得黄色针状结晶。黄色针晶用氯仿溶解,用硅胶柱层析,氯仿洗脱,收集合并紫外灯下显紫色斑点的流分,蒸干,用丙酮重结晶,得黄色长针晶,即石吊兰素。
石吊兰素有显著的抗结核杆菌、抗炎、降压作用,清除自由基等多种生物学效应。吊石苣苔中提取的酯溶性成分石吊兰素,经体外试验200g/mL即有显著的抗结核杆菌作用,体内试验亦有一定保护作用,用于淋巴结核的治疗效果显著。从吊石苣苔中提取的石吊兰素进行抗炎作用研究,结果表明石吊兰素对琼酶、五羟色胺、甲醛、高岭土所致实验性关节炎有明显抑制作用,对棉球肉芽肿也有抑制作用,其抗炎作用不依赖肾上腺皮质的存在。研究发现,给麻醉狗、猫肌肉内注射或静脉注射石吊兰素均可使血压明显降低。石吊兰素对麻醉开胸猫血流动力学研究表明,石吊兰素2.5mg/kg iv降压时伴有左室内压峰值及外周阻力下降;5mg/kg iv使外周阻力及血压进一步降低,舒张压的下降超过收缩压,心率减慢,心输出量及左室内压上升速率峰值等均见明显降低。低剂量石吊兰素的降压作用主要系舒展血管所致,石吊兰素较大剂量对心脏的抑制作用可能也参与了降压成分。许多研究指出,冠心病患者心肌缺血状态下,自由基增多,酯质过氧化作用增强,而肌体抗氧化作用降低,不能清除体内过量的氧自由基,致使细胞膜损伤及功能障碍。天然石吊兰素能有效地清除自由基,石吊兰素酚羟基是清除自由基的主要活性基团。研究发现石吊兰素能抑制肝癌细胞生长。近年来用石吊兰醇提取液对荷S180实体瘤小鼠体内抗肿瘤作用,分析对其免疫功能的影响。研究结果显示,石吊兰醇提取液具有抑制对荷S180实体瘤生长及提高荷瘤小鼠免疫功能的作用。
随着从药用植物中提取低成本、高收率和高纯度的石吊兰素的技术工艺逐步完善,以及石吊兰素的生物活性不断被揭示及其在应用领域不断扩展,定会大幅度地提高富含石吊兰素的药用植物在中药复方中的医用价值,开发前景十分广阔。
发明内容
本发明所要解决的技术问题是提供一种能有效改善猪腹泻,且毒副作用低的猪饲料添加剂。
本发明解决上述问题所采用的技术方案是,提供一种防治猪腹泻的饲料添加剂,其中活性成分黄连素与石吊兰素的重量比为(1:10)~(10:1)。
优选的,所述饲料添加剂中黄连素与石吊兰素的重量比为(1:1)~(1:9)。
更优选的,黄连素与石吊兰素的重量比为1:4。
优选的,所述饲料添加剂进一步包括其他活性成分。
更优选的,所述其他活性成分选自氨基酸、维生素等中的一种或多种。
最优选的,所述氨基酸为蛋氨酸、赖氨酸和/或苏氨酸等,所述维生素为维生素A、维生素C和/或维生素E等。
本发明还提供一种上述饲料添加剂在制备防治猪腹泻的饲料中的应用。
优选的,所述100重量份的饲料中,含有1-10重量%的饲料添加剂。
本发明具有积极有益的效果:
令人惊奇的是,本发明意外发现将黄连素与石吊兰素组合使用对于防治猪腹泻具有协同增效的效果,配合其他活性成分使用效果更佳。
与普通饲料添加剂相比,本发明的猪饲料添加剂制备方法简单,配伍合理,疗效显著,能够显著降低猪腹泻率,实验证明对改善猪腹泻有特效;由于添加剂中无西药成分,因此饲料添加剂无毒副作用,无耐药性。
具体实施方式
下面结合实施例对本发明作更进一步的说明,但本发明的实施方式不限于此。下述实施例中所使用的实验方法如无特殊说明,均为常规方法。
实施例1、饲料添加剂的制备
取黄连素5重量份,石吊兰素5重量份,混合后制成黄连素和石吊兰素重量比为1:1的饲料添加剂A1。
取黄连素2重量份,石吊兰素8重量份,混合后制成黄连素和石吊兰素重量比为1:4的饲料添加剂A2。
取黄连素1重量份,石吊兰素9重量份,混合后制成黄连素和石吊兰素重量比为1:9的饲料添加剂A3。
实施例2、本发明饲料添加剂在防治猪腹泻中的应用
为验证本发明的应用效果,本发明的饲料添加剂在健康、体重相近的猪仔中进行试验。将猪分为本发明中药组合物组(3组分别使用实施例1制备的饲料添加剂A1-A3)、黄连素组、石吊兰素组和对照组,每组各为50只。其中,A1-A3中药组合物组、黄连素组、石吊兰素组的日粮按照饲料总重量的1%添加上述饲料添加剂(每组加入的中药活性成分总量相同),对照组的日粮为不添加上述饲料添加剂的相同重量的猪饲料,各组猪每日投喂3次,试验期内自由采食,同时提供充足的饮水,其他各项日常管理措施按照养殖场的常规管理进行,定期进行免疫和驱虫,45天后统计试验期内各组中猪的发病情况,并计算各组的猪腹泻率(见表1)。
表1
试验分组 | 腹泻头数 | 腹泻率 |
对照组 | 16 | 32% |
黄连素组 | 10 | 20% |
石吊兰素组 | 13 | 26% |
黄连素+石吊兰素(1:1) | 7 | 14% |
黄连素+石吊兰素(1:4) | 2 | 4% |
黄连素+石吊兰素(1:9) | 5 | 10% |
由实施例2可以看出,本发明的饲料添加剂能有效防治猪腹泻,提高仔猪免疫力,降低猪的腹泻率,特别是黄连素和石吊兰素的组合使用产生了协同效果,减少了药物的使用量,其中黄连素和石吊兰素重量比为1:4的饲料添加剂效果最为突出,产生了难以预期的优异效果。
Claims (8)
1.一种防治猪腹泻的饲料添加剂,其特征在于,其中活性成分黄连素与石吊兰素的重量比为(1:10)~(10:1)。
2.根据权利要求1所述的饲料添加剂,其特征在于,黄连素与石吊兰素的重量比为(1:1)~(1:9)。
3.根据权利要求2所述的饲料添加剂,其特征在于,黄连素与石吊兰素的重量比为1:4。
4.根据权利要求1所述的饲料添加剂,其特征在于,所述饲料添加剂进一步包括其他活性成分。
5.根据权利要求4所述的饲料添加剂,其特征在于,所述其他活性成分选自氨基酸、维生素中的一种或两种。
6.根据权利要求5所述的饲料添加剂,其特征在于,所述氨基酸选自蛋氨酸、赖氨酸和/或苏氨酸,所述维生素选自维生素A、维生素C和/或维生素E。
7.权利要求1-6任一项所述的饲料添加剂在制备防治猪腹泻的饲料中的应用。
8.根据权利要求7所述的应用,其特征在于,所述100重量份的饲料中,含有1-10重量%的饲料添加剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710748510.0A CN107307214B (zh) | 2017-08-28 | 2017-08-28 | 一种治疗猪腹泻的饲料添加剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710748510.0A CN107307214B (zh) | 2017-08-28 | 2017-08-28 | 一种治疗猪腹泻的饲料添加剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107307214A true CN107307214A (zh) | 2017-11-03 |
CN107307214B CN107307214B (zh) | 2018-11-06 |
Family
ID=60176936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710748510.0A Active CN107307214B (zh) | 2017-08-28 | 2017-08-28 | 一种治疗猪腹泻的饲料添加剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107307214B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108464276A (zh) * | 2018-05-30 | 2018-08-31 | 凌云县郁丰农业专业合作社联合社 | 一种彩豚的繁育方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103549222A (zh) * | 2013-11-22 | 2014-02-05 | 安徽科技学院 | 一种抗仔猪腹泻的复合饲料添加剂及其制备方法 |
CN104366073A (zh) * | 2014-11-03 | 2015-02-25 | 河南联合英伟饲料有限公司 | 一种4%功能性无抗仔猪预混料 |
CN106912732A (zh) * | 2017-04-25 | 2017-07-04 | 中国热带农业科学院热带生物技术研究所 | 一种治疗猪腹泻的饲料添加剂及其应用 |
CN106983765A (zh) * | 2017-05-15 | 2017-07-28 | 江苏省农业科学院 | 一种防治猪圆环病毒病的中药成分方剂及其制备方法和应用 |
-
2017
- 2017-08-28 CN CN201710748510.0A patent/CN107307214B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103549222A (zh) * | 2013-11-22 | 2014-02-05 | 安徽科技学院 | 一种抗仔猪腹泻的复合饲料添加剂及其制备方法 |
CN104366073A (zh) * | 2014-11-03 | 2015-02-25 | 河南联合英伟饲料有限公司 | 一种4%功能性无抗仔猪预混料 |
CN106912732A (zh) * | 2017-04-25 | 2017-07-04 | 中国热带农业科学院热带生物技术研究所 | 一种治疗猪腹泻的饲料添加剂及其应用 |
CN106983765A (zh) * | 2017-05-15 | 2017-07-28 | 江苏省农业科学院 | 一种防治猪圆环病毒病的中药成分方剂及其制备方法和应用 |
Non-Patent Citations (6)
Title |
---|
丁安伟: "《现代中药临床手册》", 31 August 2000, 江苏科学技术出版社 * |
于化洲: "《中小型猪场猪病综合防治》", 31 January 2014, 金盾出版社 * |
刁有祥: "《鸡场用药手册》", 31 March 2014, 金盾出版社 * |
纪承寅等: "《同药异名速查手册》", 31 January 2005, 军事医学科学出版社 * |
谢惠民: "《合理用药》", 30 November 1996, 人民卫生出版社 * |
贾公孚等: "《临床药物新用联用大全》", 31 August 1999, 人民卫生出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108464276A (zh) * | 2018-05-30 | 2018-08-31 | 凌云县郁丰农业专业合作社联合社 | 一种彩豚的繁育方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107307214B (zh) | 2018-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102614288B (zh) | 一种防治鸡大肠杆菌疾病的中药微生态制剂及其制备方法 | |
EP2236149B1 (en) | Medicinal composition for treating respiratory infectious diseases | |
CN104257844B (zh) | 一种治疗猪高热病的中药散剂及其制备工艺 | |
CN105287790B (zh) | 一种鸡矢藤提取物及其应用 | |
CN104922176B (zh) | 一种野菊花提取物的应用 | |
CN105935364B (zh) | 用于预防或治疗非酒精性肝病的包含人参皂苷f2的组合物 | |
Meliboeva et al. | The effect of broccoli sprouts on diabetes mellitus and the gastrointestinal tract | |
CN107648326B (zh) | 一种禽畜用苋黄止痢口服液的制备方法 | |
KR101829637B1 (ko) | 참옻나무 목심 추출물을 함유하는 항암치료 부작용에 따른 소화기능장애, 백혈구 감소증 및 골수부전증의 개선, 예방 또는 치료용 조성물 | |
CN102920771B (zh) | 一种用于治疗家禽球虫病的药物 | |
JP6444515B2 (ja) | タウリンのコロナウイルス属及び/又はロタウイルス属のウィルスにより引き起こされる疾患の予防及び/又は治療における応用 | |
CN107307214B (zh) | 一种治疗猪腹泻的饲料添加剂 | |
JP6592010B2 (ja) | 癌細胞増殖抑制組成物および癌細胞増殖の抑制方法 | |
WO2015115865A1 (ko) | 아르테수네이트 또는 감마리놀렌산을 포함하는 결핵의 치료 및 예방용 항결핵 조성물 | |
JP6662678B2 (ja) | 癌細胞増殖抑制組成物 | |
JP5903280B2 (ja) | 整腸剤、便通改善剤、及び便秘改善剤 | |
CN107812166A (zh) | 一种预防鱼类急性肠胃炎的饲料添加剂及其制备方法 | |
KR101765988B1 (ko) | 고련피 추출물 또는 이의 분획물을 포함하는 결핵의 치료 및 예방용 항결핵 조성물 | |
CN105770054A (zh) | 用于防治鸡球虫病的药物组合物、添加剂和饲料 | |
US20150050372A1 (en) | Extract of rhus copallina as pharmaceutical | |
KR101798286B1 (ko) | 리놀렌산을 유효성분으로 포함하는 결핵의 치료 또는 예방용 조성물 | |
CN107789394A (zh) | 一种用于治疗畜禽腹泻的组合物 | |
CN115837051B (zh) | 一种复合型虫草素制剂及其制备方法与在制备抗小细胞肺癌产品中的应用 | |
CN108338981B (zh) | 黄肉楠碱在制备抗贝氏隐孢子虫药物中的应用 | |
CN107961284B (zh) | 一种防治仔猪腹泻的口服制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180913 Address after: 336000 Jiangxi Yichun economic and Technological Development Zone Industrial Road Applicant after: Yichun lush Feed Co., Ltd. Address before: No. 102, building No. 102, Huizhong Li, Beijing, Beijing Applicant before: Zhu Wei |
|
GR01 | Patent grant | ||
GR01 | Patent grant |